Thomas J Martin, Conner W Martin, Kevin J Frankowski, Bruce E Blough, Jeffrey Aubé, Laura M Bohn, Sara R Jones
{"title":"腹腔内乳酸对雄性和雌性大鼠颅内自我刺激的抑制作用:吗啡、酮洛芬的作用以及与g蛋白偏性阿片受体激动剂的相互作用","authors":"Thomas J Martin, Conner W Martin, Kevin J Frankowski, Bruce E Blough, Jeffrey Aubé, Laura M Bohn, Sara R Jones","doi":"10.1007/s00213-025-06800-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Numerous pharmacological classes of compounds have been explored as novel and efficacious alternatives to standard mu opioid agonist analgesics. We and others have described G-protein biased kappa opioid agonists as having potential utility as analgesics due to a lower propensity to produce sedation and dysphoria, which are thought to be mediated in large part through beta-arrestin signaling.</p><p><strong>Methods: </strong>Here we compare two G-protein biased kappa agonists that differ in their basic chemical scaffold, triazole 1.1 (Tr1.1) and isoquinolinone 2.1 (Iso2.1), for alteration of intracranial self-stimulation (ICSS) in male and female rats. Lactic acid (LA) was given i.p. at a concentration sufficient to produce moderate to severe depression of ICSS.</p><p><strong>Results: </strong>Neither Tr1.1 nor Iso2.2 reversed the effects of lactic acid at concentrations that produced significant depression of ICSS in either sex. Neither drug altered ICSS in the absence of lactic acid administration. In both males and females, morphine reversed the effects of i.p. lactic acid on ICSS and co-administration of Tr1.1 did not alter the dose-effect curve for morphine in either sex. Similar effects were observed for ketoprofen. Ketoprofen also reversed the effects of i.p. lactic acid on ICSS in both sexes in a dose-dependent manner, and co-administration of neither Tr1.1 nor Iso2.1 altered the ketoprofen dose-effect curve.</p><p><strong>Conclusions: </strong>These data suggest that these G-protein biased kappa agonists may lack sufficient efficacy or potency to alter the effects of opioids or NSAIDs against moderate to severe antinociceptive stimuli in rats, and development of more potent or efficacious compounds may be required to demonstrate efficacy in rat models of moderate to severe nociception.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Depression of intracranial self-stimulation in male and female rats by intraperitoneal lactic acid: effects of morphine, ketoprofen, and interactions with G-protein biased kappa opioid agonists.\",\"authors\":\"Thomas J Martin, Conner W Martin, Kevin J Frankowski, Bruce E Blough, Jeffrey Aubé, Laura M Bohn, Sara R Jones\",\"doi\":\"10.1007/s00213-025-06800-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Numerous pharmacological classes of compounds have been explored as novel and efficacious alternatives to standard mu opioid agonist analgesics. We and others have described G-protein biased kappa opioid agonists as having potential utility as analgesics due to a lower propensity to produce sedation and dysphoria, which are thought to be mediated in large part through beta-arrestin signaling.</p><p><strong>Methods: </strong>Here we compare two G-protein biased kappa agonists that differ in their basic chemical scaffold, triazole 1.1 (Tr1.1) and isoquinolinone 2.1 (Iso2.1), for alteration of intracranial self-stimulation (ICSS) in male and female rats. Lactic acid (LA) was given i.p. at a concentration sufficient to produce moderate to severe depression of ICSS.</p><p><strong>Results: </strong>Neither Tr1.1 nor Iso2.2 reversed the effects of lactic acid at concentrations that produced significant depression of ICSS in either sex. Neither drug altered ICSS in the absence of lactic acid administration. In both males and females, morphine reversed the effects of i.p. lactic acid on ICSS and co-administration of Tr1.1 did not alter the dose-effect curve for morphine in either sex. Similar effects were observed for ketoprofen. Ketoprofen also reversed the effects of i.p. lactic acid on ICSS in both sexes in a dose-dependent manner, and co-administration of neither Tr1.1 nor Iso2.1 altered the ketoprofen dose-effect curve.</p><p><strong>Conclusions: </strong>These data suggest that these G-protein biased kappa agonists may lack sufficient efficacy or potency to alter the effects of opioids or NSAIDs against moderate to severe antinociceptive stimuli in rats, and development of more potent or efficacious compounds may be required to demonstrate efficacy in rat models of moderate to severe nociception.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06800-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06800-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Depression of intracranial self-stimulation in male and female rats by intraperitoneal lactic acid: effects of morphine, ketoprofen, and interactions with G-protein biased kappa opioid agonists.
Introduction: Numerous pharmacological classes of compounds have been explored as novel and efficacious alternatives to standard mu opioid agonist analgesics. We and others have described G-protein biased kappa opioid agonists as having potential utility as analgesics due to a lower propensity to produce sedation and dysphoria, which are thought to be mediated in large part through beta-arrestin signaling.
Methods: Here we compare two G-protein biased kappa agonists that differ in their basic chemical scaffold, triazole 1.1 (Tr1.1) and isoquinolinone 2.1 (Iso2.1), for alteration of intracranial self-stimulation (ICSS) in male and female rats. Lactic acid (LA) was given i.p. at a concentration sufficient to produce moderate to severe depression of ICSS.
Results: Neither Tr1.1 nor Iso2.2 reversed the effects of lactic acid at concentrations that produced significant depression of ICSS in either sex. Neither drug altered ICSS in the absence of lactic acid administration. In both males and females, morphine reversed the effects of i.p. lactic acid on ICSS and co-administration of Tr1.1 did not alter the dose-effect curve for morphine in either sex. Similar effects were observed for ketoprofen. Ketoprofen also reversed the effects of i.p. lactic acid on ICSS in both sexes in a dose-dependent manner, and co-administration of neither Tr1.1 nor Iso2.1 altered the ketoprofen dose-effect curve.
Conclusions: These data suggest that these G-protein biased kappa agonists may lack sufficient efficacy or potency to alter the effects of opioids or NSAIDs against moderate to severe antinociceptive stimuli in rats, and development of more potent or efficacious compounds may be required to demonstrate efficacy in rat models of moderate to severe nociception.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.